VBI Vaccines Inc.
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-26…
Biotechnology
US, Cambridge [HQ]
Insiders
Transactions
Track non-derivative insider transactions.
i = Indirect Ownership
d = Direct Ownership
cs = Common Stock
| Reported Owner(s) | Position Now | Transaction Date | Type | Position Change | Extra | ||
|---|---|---|---|---|---|---|---|
|
$1,043,292
i
Common Shares, no par value per share
10% Holder
|
07/10/23 |
P
|
609,090 x $1.65 = $1,004,998.50 |
Footnotes
#1 The 609,090 common shares reported in Table I and accompanying warrants to purchase up to 609,090 common shares reported in Table II of this Form 4 were purchased together at a combined public offering price of $1.65 per share and accompanying warrant, which such combined public offering price included $0.01 per accompanying warrant.
#2 Includes 100,869 common shares held of record by ARCH Venture Fund VI, L.P. ("ARCH VI") and 942,423 common shares held of record by ARCH Venture Fund X Overage, L.P. (the "ARCH Overage"). ARCH Venture Partners VI, L.P. (the "ARCH GPLP"), as the sole general partner of ARCH VI, may be deemed to beneficially own certain of the shares held of record by ARCH VI. The ARCH GPLP disclaims beneficial ownership of all shares held of record by ARCH VI in which the ARCH GPLP does not have an actual pecuniary interest. ARCH Venture Partners VI, LLC (the "ARCH GPLLC"), as the sole general partner of the ARCH GPLP, may be deemed to beneficially own certain of the shares held of record by ARCH VI. The ARCH GPLLC disclaims beneficial ownership of all shares held of record by ARCH GPLP in which the ARCH GPLLC does not have an actual pecuniary interest.
#3 ARCH Venture Partners X Overage, L.P. (the "Overage GPLP"), as the sole general partner of ARCH Overage, may be deemed to beneficially own certain of the shares held of record by ARCH Overage. The Overage GPLP disclaims beneficial ownership of all shares held of record by ARCH Overage in which the Overage GPLP does not have an actual pecuniary interest. ARCH Venture Partners X, LLC (the "Overage GPLLC"), as the sole general partner of the Overage GPLP, may be deemed to beneficially own certain of the shares held of record by ARCH Overage. The Overage GPLLC disclaims beneficial ownership of all shares held of record by Overage GPLP in which the Overage GPLLC does not have an actual pecuniary interest.
#4 The reporting person owns an interest in ARCH GPLP but does not have voting or investment control over the shares held by ARCH VI, and disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The reporting person owns an interest in Overage GPLP and may be deemed to have voting and investment control over the shares held by ARCH Overage as member of the investment committee of Overage GPLLC, but disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
|
|||
|
$68,200
d
Common Shares, no par value per share
10% Holder
|
12/03/21 |
P
|
8,200 x $2.45 = $20,090.00 |
Footnotes
#1 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.4492 to $2.455, inclusive. The reporting person undertakes to provide to VBI Vaccines Inc., any security holder of VBI Vaccines Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
|
|||
Statistics
Sample Size: 2 Transactions
Sale (S)
0 Shares
0.00%
Buy (P)
617,290 Shares
100.00%
Individuals
We summarize earnings call passages, compensations, insider transactions and other information for each individual to get the bigger picture:
- Anderson David Evander Chief Scientific Officer
- Bain Linda Director
- Baxter Jeff CEO, President
- Beattie Nell CFO, Head of Corp. Development
- Braga Damian Director
- Cordeiro Joanne Director
- Dewilde Michel Director
- Diaz-Mitoma Francisco Chief Medical Officer
- Dillman John Robert Chief Commercial Officer
- Gillis Steven Director
- Himes Vaughn B Director
- Mazaltov Avi Head Global MFG&GM-SciVac Ltd.
- Mckee Blaine H. Director
- Mcnulty Christopher CFO and Head of BD
Individuals
We summarize earnings call passages, compensations, insider transactions and other information for each individual to get the bigger picture:
- Anderson David Evander Chief Scientific Officer
- Bain Linda Director
- Baxter Jeff CEO, President
- Beattie Nell CFO, Head of Corp. Development
- Braga Damian Director
- Cordeiro Joanne Director
- Dewilde Michel Director
- Diaz-Mitoma Francisco Chief Medical Officer
- Dillman John Robert Chief Commercial Officer
- Gillis Steven Director
- Himes Vaughn B Director
- Mazaltov Avi Head Global MFG&GM-SciVac Ltd.
- Mckee Blaine H. Director
- Mcnulty Christopher CFO and Head of BD